Gemcitabine therapeutically disrupts essential SIRT1-mediated p53 repression in Atypical Teratoid/Rhabdoid Tumors
D. S. Metselaar, M. H. Meel, J. R. Goulding…·E. Hulleman
This study shows gemcitabine selectively kills ATRT by degrading SIRT1, activating p53 and SHH signaling, and significantly improves survival in xenograft models.